JP5325065B2 - 新規フェノール誘導体 - Google Patents

新規フェノール誘導体 Download PDF

Info

Publication number
JP5325065B2
JP5325065B2 JP2009227402A JP2009227402A JP5325065B2 JP 5325065 B2 JP5325065 B2 JP 5325065B2 JP 2009227402 A JP2009227402 A JP 2009227402A JP 2009227402 A JP2009227402 A JP 2009227402A JP 5325065 B2 JP5325065 B2 JP 5325065B2
Authority
JP
Japan
Prior art keywords
group
added
mixture
solvent
reduced pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009227402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011074017A (ja
Inventor
精一 小橋
淳一郎 雨田
幸帆 宮田
勗 井上
直樹 芦澤
浩二 松本
哲也 谷口
崇 岩永
治 永田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujiyakuhin Co Ltd
Original Assignee
Fujiyakuhin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43826265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5325065(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujiyakuhin Co Ltd filed Critical Fujiyakuhin Co Ltd
Priority to JP2009227402A priority Critical patent/JP5325065B2/ja
Priority to MYPI2012001060A priority patent/MY160394A/en
Priority to AU2010301675A priority patent/AU2010301675B2/en
Priority to US13/499,190 priority patent/US8367843B2/en
Priority to DK10820564.2T priority patent/DK2484669T3/en
Priority to PL10820564T priority patent/PL2484669T3/pl
Priority to CA2775309A priority patent/CA2775309C/en
Priority to PT108205642T priority patent/PT2484669E/pt
Priority to CN201080042866.9A priority patent/CN102639518B/zh
Priority to ES10820564.2T priority patent/ES2549603T3/es
Priority to IN2551DEN2012 priority patent/IN2012DN02551A/en
Priority to MX2012003392A priority patent/MX2012003392A/es
Priority to TW099132910A priority patent/TWI461195B/zh
Priority to NZ598582A priority patent/NZ598582A/xx
Priority to EP10820564.2A priority patent/EP2484669B1/en
Priority to PH1/2012/500643A priority patent/PH12012500643A1/en
Priority to KR1020127007939A priority patent/KR101647174B1/ko
Priority to BR112012007069-0A priority patent/BR112012007069B1/pt
Priority to PCT/JP2010/066925 priority patent/WO2011040449A1/ja
Priority to HUE10820564A priority patent/HUE026007T2/en
Priority to RU2012117786/04A priority patent/RU2536689C2/ru
Priority to HK12110248.5A priority patent/HK1169650B/xx
Publication of JP2011074017A publication Critical patent/JP2011074017A/ja
Priority to IL218519A priority patent/IL218519A/en
Priority to ZA2012/01895A priority patent/ZA201201895B/en
Publication of JP5325065B2 publication Critical patent/JP5325065B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009227402A 2009-09-30 2009-09-30 新規フェノール誘導体 Active JP5325065B2 (ja)

Priority Applications (24)

Application Number Priority Date Filing Date Title
JP2009227402A JP5325065B2 (ja) 2009-09-30 2009-09-30 新規フェノール誘導体
TW099132910A TWI461195B (zh) 2009-09-30 2010-09-29 Novel phenol derivatives
EP10820564.2A EP2484669B1 (en) 2009-09-30 2010-09-29 Phenol derivatives
US13/499,190 US8367843B2 (en) 2009-09-30 2010-09-29 Phenol derivative
DK10820564.2T DK2484669T3 (en) 2009-09-30 2010-09-29 Fenolderivat
PL10820564T PL2484669T3 (pl) 2009-09-30 2010-09-29 Pochodne fenolu
CA2775309A CA2775309C (en) 2009-09-30 2010-09-29 A phenol derivative and its pharmaceutical use
PT108205642T PT2484669E (pt) 2009-09-30 2010-09-29 Derivados de fenol
CN201080042866.9A CN102639518B (zh) 2009-09-30 2010-09-29 新型苯酚衍生物
ES10820564.2T ES2549603T3 (es) 2009-09-30 2010-09-29 Derivados de fenol
IN2551DEN2012 IN2012DN02551A (enExample) 2009-09-30 2010-09-29
MX2012003392A MX2012003392A (es) 2009-09-30 2010-09-29 Nuevo derivado de fenol.
MYPI2012001060A MY160394A (en) 2009-09-30 2010-09-29 Novel phenol derivative
NZ598582A NZ598582A (en) 2009-09-30 2010-09-29 Novel phenol derivative having uricsuric effect
AU2010301675A AU2010301675B2 (en) 2009-09-30 2010-09-29 Novel phenol derivative
PH1/2012/500643A PH12012500643A1 (en) 2009-09-30 2010-09-29 Novel phenol derivative
KR1020127007939A KR101647174B1 (ko) 2009-09-30 2010-09-29 신규 페놀 유도체
BR112012007069-0A BR112012007069B1 (pt) 2009-09-30 2010-09-29 Derivado de fenol, e composição farmacêutica compreendo o mesmo
PCT/JP2010/066925 WO2011040449A1 (ja) 2009-09-30 2010-09-29 新規フェノール誘導体
HUE10820564A HUE026007T2 (en) 2009-09-30 2010-09-29 Phenol derivatives
RU2012117786/04A RU2536689C2 (ru) 2009-09-30 2010-09-29 Новое производное фенола
HK12110248.5A HK1169650B (en) 2009-09-30 2010-09-29 Novel phenol derivative
IL218519A IL218519A (en) 2009-09-30 2012-03-07 Phenol sequel
ZA2012/01895A ZA201201895B (en) 2009-09-30 2012-03-14 Novel phenol derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009227402A JP5325065B2 (ja) 2009-09-30 2009-09-30 新規フェノール誘導体

Publications (2)

Publication Number Publication Date
JP2011074017A JP2011074017A (ja) 2011-04-14
JP5325065B2 true JP5325065B2 (ja) 2013-10-23

Family

ID=43826265

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009227402A Active JP5325065B2 (ja) 2009-09-30 2009-09-30 新規フェノール誘導体

Country Status (23)

Country Link
US (1) US8367843B2 (enExample)
EP (1) EP2484669B1 (enExample)
JP (1) JP5325065B2 (enExample)
KR (1) KR101647174B1 (enExample)
CN (1) CN102639518B (enExample)
AU (1) AU2010301675B2 (enExample)
BR (1) BR112012007069B1 (enExample)
CA (1) CA2775309C (enExample)
DK (1) DK2484669T3 (enExample)
ES (1) ES2549603T3 (enExample)
HU (1) HUE026007T2 (enExample)
IL (1) IL218519A (enExample)
IN (1) IN2012DN02551A (enExample)
MX (1) MX2012003392A (enExample)
MY (1) MY160394A (enExample)
NZ (1) NZ598582A (enExample)
PH (1) PH12012500643A1 (enExample)
PL (1) PL2484669T3 (enExample)
PT (1) PT2484669E (enExample)
RU (1) RU2536689C2 (enExample)
TW (1) TWI461195B (enExample)
WO (1) WO2011040449A1 (enExample)
ZA (1) ZA201201895B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5851802B2 (ja) 2011-03-30 2016-02-03 富士重工業株式会社 炭素繊維強化樹脂複合材用ドリル
WO2015191034A1 (en) * 2014-06-09 2015-12-17 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
WO2017038799A1 (ja) * 2015-09-04 2017-03-09 サントリーホールディングス株式会社 ウレアーゼ活性阻害剤
CA2998034C (en) * 2015-09-10 2021-05-04 Dongfang Shi A group of compounds used for the treatment or prevention of hyperuricemia or gout
CN105675557B (zh) * 2016-01-07 2019-01-25 济南大学 基于苯炔荧光试剂检测硫脲含量的新方法
KR102610573B1 (ko) 2016-07-18 2023-12-05 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증과 관련된 증상의 치료 또는 예방을 위한 화합물, 조성물 및 방법
SG11201909747WA (en) * 2017-04-28 2019-11-28 Fuji Yakuhin Co Ltd Crystal form and salt of 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole
CN109928890B (zh) * 2017-12-15 2021-11-09 重庆常捷医药有限公司 一种托伐普坦中间体2-甲基-4-n-(2-甲基苯甲酰)苯甲酸的制备方法
BR112021010708A2 (pt) 2018-12-06 2021-08-24 Arthrosi Therapeutics, Inc. Formas cristalinas de um composto para tratar ou prevenir gota ou hiperuricemia
AU2019392750B2 (en) 2018-12-06 2025-07-10 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
CA3159300A1 (en) * 2019-12-09 2021-06-17 Tadashi Inoue Solid pharmaceutical preparation
CN111662247A (zh) * 2020-07-17 2020-09-15 苏州明锐医药科技有限公司 一种多替诺德的合成方法
CN111675675A (zh) * 2020-07-17 2020-09-18 苏州明锐医药科技有限公司 多替诺德的制备方法
CN112430221B (zh) * 2020-11-20 2023-06-23 成都诺和晟泰生物科技有限公司 用于预防、治疗或减轻高尿酸血症或痛风的化合物及其应用
WO2022169974A1 (en) 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof
CN114903879B (zh) * 2022-06-23 2023-10-31 东北大学 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途
CN115160314B (zh) * 2022-07-28 2023-12-05 南方医科大学 杂环芳酰胺类化合物及其制备方法和应用
WO2025085662A1 (en) 2023-10-17 2025-04-24 Vanderbilt University Compounds for tocolytic use
CN118580197A (zh) * 2023-11-16 2024-09-03 广东东阳光药业股份有限公司 一种多替诺雷制备方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720683A (en) * 1970-09-02 1973-03-13 Squibb & Sons Inc 2-phenyl-3-acylbenzothiazolines and their oxides
WO2005121112A1 (ja) 2004-06-10 2005-12-22 Torii Pharmaceutical Co., Ltd. ６－ヒドロキシベンズブロマロン又はその塩からなる医薬組成物
JP3988832B2 (ja) 2004-11-29 2007-10-10 日本たばこ産業株式会社 窒素含有縮合環化合物及びその用途
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
EP1985297A1 (en) * 2006-01-27 2008-10-29 Japan Tobacco, Inc. Carboxylic acid compound and use thereof
US20080305169A1 (en) * 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
US20080064871A1 (en) * 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
WO2008062740A1 (fr) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Composé azoté à anneaux fusionnés et son utilisation

Also Published As

Publication number Publication date
EP2484669A4 (en) 2013-02-27
KR101647174B1 (ko) 2016-08-09
NZ598582A (en) 2013-04-26
CA2775309A1 (en) 2011-04-07
PL2484669T3 (pl) 2015-12-31
RU2536689C2 (ru) 2014-12-27
RU2012117786A (ru) 2013-11-10
HUE026007T2 (en) 2016-05-30
BR112012007069A2 (pt) 2016-04-19
IL218519A0 (en) 2012-07-31
ES2549603T3 (es) 2015-10-29
IN2012DN02551A (enExample) 2015-08-28
KR20120080183A (ko) 2012-07-16
ZA201201895B (en) 2013-09-25
MX2012003392A (es) 2012-04-10
WO2011040449A1 (ja) 2011-04-07
DK2484669T3 (en) 2015-09-21
HK1169650A1 (en) 2013-02-01
EP2484669A1 (en) 2012-08-08
PT2484669E (pt) 2015-10-30
TW201121544A (en) 2011-07-01
US20120184587A1 (en) 2012-07-19
TWI461195B (zh) 2014-11-21
AU2010301675A1 (en) 2012-04-05
JP2011074017A (ja) 2011-04-14
BR112012007069B1 (pt) 2020-03-03
CN102639518B (zh) 2015-03-25
CN102639518A (zh) 2012-08-15
EP2484669B1 (en) 2015-07-29
PH12012500643A1 (en) 2012-11-12
CA2775309C (en) 2017-12-12
MY160394A (en) 2017-03-15
IL218519A (en) 2016-03-31
AU2010301675B2 (en) 2013-08-22
US8367843B2 (en) 2013-02-05

Similar Documents

Publication Publication Date Title
JP5325065B2 (ja) 新規フェノール誘導体
WO2007097403A1 (ja) 消化管潰瘍治療又は予防薬
EP1419770A1 (en) Apo ai expression accelerating agent
JP4894517B2 (ja) ２−フェニルピリジン誘導体
WO2006022375A1 (ja) ２－フェニルチオフェン誘導体
JP3295277B2 (ja) 抗腎疾患剤及びベンズイミダゾール誘導体
JP2008088107A (ja) 新規ピリダジン誘導体
WO2019208635A1 (ja) 縮合ピリミジン誘導体
WO2007004688A1 (ja) キサンチンオキシダーゼ阻害剤
JPWO2006132438A1 (ja) １，３−ベンゾチアジノン誘導体およびその用途
TWI687418B (zh) 唑苯衍生物之結晶
JPH0499770A (ja) ロダニン誘導体
JP2003267870A (ja) 肺高血圧症の予防又は治療剤
KR20170033320A (ko) 아조르벤젠 유도체 및 그 결정
WO2022121222A1 (zh) 吡啶巯乙酸类化合物及其制备方法、药学衍生物或配剂以及应用
WO2021162054A1 (ja) ２型リアノジン受容体活性抑制剤
CA2589718A1 (en) Tetrazolyl-methylene amino acid derivatives
JP2003335670A (ja) 癒着防止剤
HK1169650B (en) Novel phenol derivative
JPH06100541A (ja) ピラゾリノン誘導体
TW201221127A (en) Sulfamide derivatives having NPY Y5 receptor antagonistic activity

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120410

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20130410

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20130424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130514

TRDD Decision of grant or rejection written
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130620

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130709

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130719

R150 Certificate of patent or registration of utility model

Ref document number: 5325065

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250